Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity

Acta Pharmaceutica Sinica. B
Yu FuLing Zhang

Abstract

The T cell co-stimulatory molecule OX40 and its cognate ligand OX40L have attracted broad research interest as a therapeutic target in T cell-mediated diseases. Accumulating preclinical evidence highlights the therapeutic efficacy of both agonist and blockade of the OX40-OX40L interaction. Despite this progress, many questions about the immuno-modulator roles of OX40 on T cell function remain unanswered. In this review we summarize the impact of the OX40-OX40L interaction on T cell subsets, including Th1, Th2, Th9, Th17, Th22, Treg, Tfh, and CD8+ T cells, to gain a comprehensive understanding of anti-OX40 mAb-based therapies. The potential therapeutic application of the OX40-OX40L interaction in autoimmunity diseases and cancer immunotherapy are further discussed; OX40-OX40L blockade may ameliorate autoantigen-specific T cell responses and reduce immune activity in autoimmunity diseases. We also explore the rationale of targeting OX40-OX40L interactions in cancer immunotherapy. Ligation of OX40 with targeted agonist anti-OX40 mAbs conveys activating signals to T cells. When combined with other therapeutic treatments, such as anti-PD-1 or anti-CTLA-4 blockade, cytokines, chemotherapy, or radiotherapy, the anti-tumor activity of ...Continue Reading

Citations

Jul 19, 2020·International Journal of Molecular Sciences·Cody BarbariRahul R Deshmukh
Aug 9, 2020·Frontiers in Bioengineering and Biotechnology·Chongyin HanFei Ling
Jan 14, 2021·Signal Transduction and Targeted Therapy·Xiaofei Zhou, Shao-Cong Sun
Nov 6, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Martin GutierrezIgnacio Melero
Jan 13, 2021·Cancers·Marc ArmengolGaël Roué
Feb 4, 2021·Cancers·Alessio Ugolini, Marianna Nuti
Feb 23, 2021·Biochimica Et Biophysica Acta. Reviews on Cancer·Emily De LombaerdeBruno G De Geest
Mar 13, 2021·Pharmaceutical Patent Analyst·Martin Perez-Santos
Mar 16, 2021·Frontiers in Immunology·Yun-Shiuan Olivia HsuChun-Bing Chen
Jul 20, 2021·Frontiers in Cell and Developmental Biology·Daniele E MascarelliMarcio C Bajgelman
Jul 15, 2021·Scientific Reports·Natalia Palazón-CarriónUNKNOWN Spanish Breast Cancer Group (GEICAM) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA)
Aug 10, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yu FuLing Zhang
Nov 4, 2021·Cancer Immunology, Immunotherapy : CII·Luya CaiWenfeng Li

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
biopsies

Clinical Trials Mentioned

NCT02559024
NCT02274155
NCT01862900
NCT02315066
NCT02410512
NCT03241173
NCT02221960
NCT02705482
NCT02923349

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

The Journal of Immunology : Official Journal of the American Association of Immunologists
Gillian KinnearNick D Jones
Clinical Reviews in Allergy & Immunology
Gwilym J WebbPeter J L Lane
© 2021 Meta ULC. All rights reserved